Cyclophosphamide Injection, Solution has 21 known drug interactions based on U.S. FDA drug labeling data. 9 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Busulfan, Cytarabine, Etanercept. Patients taking Cyclophosphamide Injection, Solution should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 21
- Major
- 9
- Moderate
- 11
Major (9)
- Cyclophosphamide Injection, Solution + Busulfan— Increased incidence of hepatic veno-occlusive disease and mucositis reported with concomitant use.
- Cyclophosphamide Injection, Solution + Cytarabine— Cytarabine potentiates cyclophosphamide's cardiotoxicity when used concomitantly or sequentially.
- Cyclophosphamide Injection, Solution + Etanercept— Higher incidence of non-cutaneous malignant solid tumors occurred with addition of etanercept to cyclophosphamide treatm…
- Cyclophosphamide Injection, Solution + Indomethacin— Acute water intoxication reported with concomitant use; indomethacin potentiates cyclophosphamide nephrotoxicity.
- Cyclophosphamide Injection, Solution + Metronidazole— Acute encephalopathy reported; combination associated with increased cyclophosphamide toxicity in animal studies.
- Cyclophosphamide Injection, Solution + Pentostatin— Pentostatin potentiates cyclophosphamide's cardiotoxicity when used concomitantly or sequentially.
- Cyclophosphamide Injection, Solution + Protease Inhibitors— Protease inhibitors may increase concentration of cyclophosphamide cytotoxic metabolites, associated with higher inciden…
- Cyclophosphamide Injection, Solution + Tetracycline— Anthracyclines potentiate cyclophosphamide's cardiotoxicity when used concomitantly or sequentially.
- Cyclophosphamide Injection, Solution + Trastuzumab— Trastuzumab potentiates cyclophosphamide's cardiotoxicity when used concomitantly or sequentially.
Moderate (11)
- Cyclophosphamide Injection, Solution + Amiodarone— Amiodarone potentiates cyclophosphamide's pulmonary toxicity when used concomitantly or sequentially.
- Cyclophosphamide Injection, Solution + Amphotericin B— Amphotericin B potentiates cyclophosphamide's nephrotoxicity when used concomitantly or sequentially.
- Cyclophosphamide Injection, Solution + Andthiazide— Thiazide diuretics can potentiate cyclophosphamide's hematotoxicity and immunosuppression.
- Cyclophosphamide Injection, Solution + Azathioprine— Increased risk of hepatotoxicity including liver necrosis when used with cyclophosphamide.
- Cyclophosphamide Injection, Solution + Cyclosporine— Lower serum concentrations of cyclosporine observed with concomitant cyclophosphamide, potentially reducing cyclosporine…
- Cyclophosphamide Injection, Solution + Mao Inhibitors— ACE inhibitors can cause leukopenia, potentiating cyclophosphamide's hematotoxicity and immunosuppression.
- Cyclophosphamide Injection, Solution + Natalizumab— Concomitant use may potentiate hematotoxicity and immunosuppression effects of cyclophosphamide.
- Cyclophosphamide Injection, Solution + Paclitaxel— Increased hematotoxicity reported when cyclophosphamide administered after paclitaxel infusion.
- Cyclophosphamide Injection, Solution + Tamoxifen— Concomitant use may increase risk of thromboembolic complications.
- Cyclophosphamide Injection, Solution + Warfarin— Both increased and decreased warfarin effects reported in patients receiving concomitant cyclophosphamide.
- Cyclophosphamide Injection, Solution + Zidovudine— Concomitant use may potentiate hematotoxicity and immunosuppression effects of cyclophosphamide.